CELEXA — FDA application NDA020822

Application NDA020822 · type NDA · FDA status: approved · original approval 1998-07-17

Listed sponsor: ABBVIE · ABBV company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

Product	FDA-listed trade name	Active ingredient	Dosage form	Route	Strength	Marketing status	TE code	RLD
001	CELEXA	CITALOPRAM HYDROBROMIDE	TABLET	ORAL	EQ 10MG BASE	Prescription	AB	Yes
002	CELEXA	CITALOPRAM HYDROBROMIDE	TABLET	ORAL	EQ 20MG BASE	Prescription	AB	Yes
003	CELEXA	CITALOPRAM HYDROBROMIDE	TABLET	ORAL	EQ 40MG BASE	Prescription	AB	Yes
004	CELEXA	CITALOPRAM HYDROBROMIDE	TABLET	ORAL	EQ 60MG BASE	Discontinued	not listed	No

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

No Orange Book patent or exclusivity listings joined to this application.

CITALOPRAM HYDROBROMIDE · UNII I1E9D14F36 · lmmol compound WIHMBLDNRMIGDW-UHFFFAOYSA-N · CHEMBL1200781

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.